Lung Cancer Research Findings
Home » Guardant360® » Lung Cancer Research Findings

Findings from the PENN2 Study

Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360® can increase the likelihood of finding targetable mutations.

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer1

“These results, combined with the patient satisfaction with the relative ease of providing blood rather than a solid tissue sample, suggest a clinical strategy of pursuing plasma NGS first, then tissue NGS if plasma NGS cannot detect relevant mutations.” 2

Bishal Gyawali, MD, PhD; Howard (Jack) West, MD

*JAMA Oncol. 2019;5(2):148-149.
doi:10.1001/jamaoncol.2018.4304

concordanse

for targetable alterations*
before first-line therapy (n=81)
*EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF

Study Overview

Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360® can increase the likelihood of finding targetable mutations.

Tissue has limitations beyond your control

Treatment delays


Results may be unpredictable
and incomplete

Patient burden


Repeated tissue biopsies
may expose patients to
potential adverse events

Finite resource


Tissue exhausted by histopathology stains and PD-L1 testing

Practice/staff burden


Coordination involving
multiple care team members

Relying solely on tissue leads to undergenotyping

~1 in 2 NSCLC patients are unable to get complete genomic results from tissue3

EGFR
ALK
ROSI
BRAF
MET
RET
ERBB2 (HER2)
NTRK

When to use Guardant360®

Before 1st Line Treatment

Get ahead of the challenges of tissue testing in advanced NSCLC by utilizing Guardant360® to guide 1L treatment decisions

At Disease Progression

Get genomic information on over 70+ genes relevant across multiple solid tumors including MSI-High to help find pan cancer therapies and clinical trials.

Published Data

Prospective study of 323 NSCLC patients found
Guardant360® improved alteration detection3

44_patients_agree_tissue_testing

were unable to get genomic results
from tissue biopsy

1.7x_as_many_patients

had targetable alterations* detected
by Guardant360® and tissue testing (n=82) versus tissue testing alone (n=47)
*EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF.

853.7_percentage

had an objective tumor response or stable disease based on RECIST

Reference:

1. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2019;5(2):173-180.
2. Bishal G, Howard JW. Plasma vs Tissue Next-Generation Sequencing in Non-Small Cell Lung Cancer-Either, Both, or Neither? JAMA Oncol 2019 Feb 1;5(2):148-149.
3. Aggarwal C, Thompson JC, Black TA, et. al. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. JAMA Oncol. 2019 Feb 1;5(2):173-180. doi: 10.1001/jamaoncol.2018.4305.

Message us